Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical efficacy and safety of NAI-Acne gel 3% in facial acne vulgaris
2014-001491-62Phase 2Completed
- Sponsor
- NAICONS
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acne vulgaris comparing NAI-Acne 3% gel bid with Placebo gel bid (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jul 2014; status: completed.
02
Drugs
NAI-Acne gel
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2014-001491-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001491-62.